Future FinTech (Hong Kong) Limited, a wholly-owned subsidiary of Future FinTech Group Inc., has signed a framework agreement to acquire 100% of TransGen SC Tech Limited. The agreement outlines preliminary terms for the transaction, which is expected to be completed within 90 calendar days, pending due diligence and a financial audit of TransGen. TransGen specializes in biomedical research and development, focusing on biofactor therapy and microalgal extracellular vesicle research, particularly in therapeutic areas such as diabetes and Alzheimer's disease. The acquisition aims to combine TransGen's biomedical expertise with Future FinTech's capabilities in financial technology, supporting the industrialization of TransGen's technologies and advancing its international expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Future FinTech Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN58684) on January 08, 2026, and is solely responsible for the information contained therein.